Abstract:Key PointsMuscle wasting is a debilitating condition that develops with ageing and more rapidly with inactivity (bed rest) and in various systemic diseases (for example, cancer, renal failure, chronic obstructive pulmonary disease, sepsis, HIV and trauma). Fibre atrophy primarily results from an acceleration of protein degradation, often combined with reduced protein synthesis. Treatments that prevent this activation of proteolysis or increase protein synthesis offer considerable promise to combat this debilitating process.Various types of rapid muscle wasting develop through a common transcriptional programme involving the induction of a set of atrophy-related genes (atrogenes) by forkhead box protein O (FOXO) transcription factors and reduced signalling by the PI3K–AKT–mTOR pathway.The resulting muscle weakness is a consequence of the degradation of myofibrils, which is catalysed by ubiquitin ligases that target different components of the contractile apparatus for proteasomal degradation. By contrast, the loss of endurance results from the breakdown of mitochondria via autophagy.Myostatin, an autocrine inhibitor of normal muscle growth, and its circulating homologue activin A, also trigger muscle protein loss in various catabolic states via the activation of SMAD2 and SMAD3, which function together with FOXO transcription factors.Antibodies against myostatin or activin A, or agents that block their receptor — activin A receptor, type IIB (ActRIIB) — in muscle could be a promising approach to combat muscle loss caused by cancer-associated cachexia, renal failure and ageing. Indeed, these treatments helped to preserve muscle and prolong longevity in tumour-bearing mice, and several of these treatments are currently in clinical trials.Glucocorticoids and various circulating inflammatory mediators, such as tumour necrosis factor-α (TNFα) and interleukin-6 (IL-6), have also been implicated in excessive muscle proteolysis in cachexia, but their roles in different catabolic states remain uncertain and controversial.Recent studies have increased our understanding of the biochemical mechanisms of atrophy and have identified many intracellular proteins that are crucial in muscle wasting (for example, SMADs, tripartate motif-containing protein 32 (TRIM32), nuclear factor-κB (NF-κB)) or that combat this process (for example, peroxisome proliferator-activated receptor-γ coactivator 1α (PGC1α), sirtuin1 (SIRT1) and JUNB). Their manipulation by small molecules offers many opportunities for the rational design of new treatments for this condition.

Muscle Atrophy Induced by Mechanical Unloading: Mechanisms and Potential Countermeasures

Mitigating skeletal muscle wasting in unloading and augmenting subsequent recovery

Roles of Myokines and Muscle-Derived Extracellular Vesicles in Musculoskeletal Deterioration under Disuse Conditions

Skeletal muscle atrophy: From mechanisms to treatments

Skeletal muscle immobilisation-induced atrophy: mechanistic insights from human studies

Mitochondrial Dysfunction of Skeletal Muscular Atrophy Induced with Hindlimb Unloaded.

Muscle wasting in disease: molecular mechanisms and promising therapies

Potential Therapeutic Strategies for Skeletal Muscle Atrophy

Cellular and molecular mechanisms of muscle atrophy

Global alternative splicing landscape of skeletal muscle atrophy induced by hindlimb unloading

Cellular and molecular mechanism of skeletal muscle atrophy and anti-atrophic muscle training

Exploring the Role of Oxidative Stress in Skeletal Muscle Atrophy: Mechanisms and Implications

The Impact of Disuse Muscle Atrophy on Perivascular Stem Cell Quantity and Function

Emerging Strategies Targeting Catabolic Muscle Stress Relief

Mitigating disuse-induced skeletal muscle atrophy in ageing: Resistance exercise as a critical countermeasure

Oxidative stress: roles in skeletal muscle atrophy

RNA sequencing (RNA-seq) analysis of gene expression provides new insights into hindlimb unloading-induced skeletal muscle atrophy

Prevention of muscle wasting and osteoporosis: the value of examining novel animal models

Mechanism of skeletal muscle atrophy after spinal cord injury: A narrative review

Forkhead Box O Signaling Pathway in Skeletal Muscle Atrophy

Advanced study of disuse muscle atrophy